Illumina, Inc. (NASDAQ:ILMN) has announced that it will host its 2010 Illumina R&D Day on Thursday, January 14. The event is set to begin at 5:00 pm ET that afternoon. The event will feature presentations by the company’s senior management team. Attendees will be provided with a comprehensive review the company’s product portfolio and market opportunities. Those unable to attend the event may listen to a live webcast of the meeting online at www.illumina.com. The webcast will be on the Company/Investors page of the site.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Illumina, Inc. is a developer, manufacturer and marketer of integrated systems for the large-scale analysis of genetic variation and biological function. The Company provides a comprehensive line of products and services that serve the sequencing, genotyping and gene expression markets. It also, develops and commercializes sequencing technologies used to perform a range of analyses, including whole genome re-sequencing, gene expression analysis and small ribonucleic acid (RNA) analysis. Its customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations and biotechnology companies. The Company operates in two business segments: Life Sciences and Diagnostics. On August 1, 2008, the Company acquired Avantome, Inc. The Company’s subsidiary is Solexa, Inc.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
